Los Angeles, Dec. 06, 2021 (GLOBE NEWSWIRE) — Spectrum Medical Group of Los Angeles California has just announced that it's now offering PRP (Platelet Rich Plasma) treatments to those in their area of the city. It’s another treatment that this reputable medical group offers that help make it easy for their patients to get closer to achieving optimal overall health. Dr. Adam Nia, the founder, and CEO of Spectrum Medical Group says, “We believe in providing compassionate and expert care in an attempt to have our patients one day wake up pain-free. This is not only a goal of all of us here at the Spectrum Medical Group but something that we are very passionate about. That’s why we offer such a wide variety of treatments that may help address our patients’ bodily pain issues. Now we have added unique and innovative Platelet Rich Plasma therapy into our mix of treatments that may help a patients’ overall wellbeing.”
Dr. Nia went on to talk more about what PRP is and what the doctors at the medical group hope to accomplish by administering it to their patients. He said that Platelet Rich Plasma therapy has become a hot topic in both medical and cosmetic circles because of all of the different bodily applications that it can be used for. This includes the possibility that it may help patients recover from everything from alopecia (a form of balding) to the effects of painful surgeries. The medical group’s founder and CEO stated that it is another of their many holistic treatments which aim to treat the whole body, including the mind, spirit, and emotions, to help a patient work towards optimal health and wellness. It’s a treatment that involves administering super concentrated platelet doses that often compliment some of their other procedures and it's also used to address specific localized chronic pain issues. He also discussed who should seek out this type of treatment. Something that includes those that are suffering from chronic pain due to injuries in often used areas of the body such as the shoulders, knees, and rotator cuff. Cosmetically it’s used for such purposes as being a non-invasive treatment that attempts to remedy several different types of baldness. Dr. Nia stated that they are always prepared to go over with a patient how their PRP in Los Angeles services might benefit them. It was also mentioned that Platelet Rich Plasma therapy has become a recognized and trusted form of therapy not only in the United States but also within the entire worldwide holistic medical community.
The medical group’s founder and CEO also described how this treatment is administered. It begins by taking a small blood sample from the patient and spinning it in a centrifuge to isolate the platelets. These platelets are then injected into the patient’s pain areas along with local anesthesia. This is done with the hope that the treatment will stimulate the body’s natural healing process. Mild to minimal pain for the patient is sometimes felt for up to two weeks after the procedure. He mentioned that this procedure is thought to work because platelets play an integral role in the body’s ability to heal itself. The injection site will then often produce collagen that when it matures may have the ability to reinforce the tendons, ligaments, blood vessels, and bones in the injection area. Some of the bodily issues that the treatment may help with include sciatica, joint arthritis, chronic tendonitis, ligament sprains, muscle tears, carpal tunnel syndrome, facet joint injuries, and fractures. If the treatment does take effect, patients will usually start to notice an improvement to their condition within two to six weeks of getting the PRP injection. Platelet Rich Plasma therapy has the potential to become a nice alternative to medications, physical therapy, and cortisone shots for patients seeking pain relief.
Those that would like more information on the PRP treatments and the other holistic health-related services that this chiropractor in Los Angeles offers can contact the Spectrum Medical Group by phone, email, or by sending in the form that’s found on their website.
For more information about Spectrum Medical Group, contact the company here:
Spectrum Medical Group
Dr. Amin Nia
5211 E. Washington #18
Los Angeles, CA 90040
The global war against COVID-19 has changed over the course of the past week — and changed dramatically just this past weekend.
Briefing documents posted Monday suggest the FDA might not approve Reata Pharma's kidney disease treatment — and RETA stock plummeted.
Vaccine stocks BioNTech and Moderna crumbled Monday as early reports suggested the omicron variant might lead to less severe cases of Covid.
Dr. Stephen Hoge, president of Moderna, said Sunday that there's a risk its vaccine would decrease in effectiveness due to Omicron.
The FDA has raised concerns about one of the company's key pipeline candidates in advance of a crucial meeting.
Shares of Bolt Biotherapeutics (NASDAQ: BOLT) crashed 55.8% on Monday. The steep decline came after the company presented interim data from a phase 1/2 study evaluating BDC-1001 at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress that's being held virtually this week. Investors were clearly disappointed with Bolt's interim results.
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Licensing Agreement with GSK for ARO-HSD; Interim Clinical Data Presented at The Liver Meeting On November 22, 2021, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced a licensing agreement with GlaxoSmithKline (GSK) for ARO-HSD, Arrowhead’s investigational RNAi therapeutic that is currently being evaluated in
Early indications about the severity of the new Omicron coronavirus variant are “encouraging,” President Joe Biden’s chief medical adviser said on Sunday. Dr. Anthony Fauci said that while it remains too early to draw any conclusions, preliminary reports suggest that the Omicron strain might result in less severe Covid infections compared with the Delta variant, which is now the dominant one in the U.S. Thus far, it doesn’t look like there’s a great degree of severity to it, Fauci said in an interview on CNN’s State of the Union.
Dr. Calvin Sun, Monsoon Diaries CEO, clinical assistant professor, and attending physician in emergency medicine in NYC, weighs in on the early information surrounding the Omicron variant and New York City's vaccine mandate for children ages 5-11.
Is Pfizer stock a buy after a new Covid variant emerged that could undo its Covid vaccine? Is PFE stock a buy right now?
Shares of Aeglea BioTherapeutics (NASDAQ: AGLE), a clinical-stage biopharmaceutical company, are falling today in response to mixed clinical-trial data. Investors nervous about the future of the company's lead candidate pushed the stock 36.6% lower as of 11:53 a.m. ET on Monday. Aegla BioTherapeutics' lead candidate, pegzilarginase, is an enzyme replacement therapy for patients with an ultra-rare amino-acid metabolism disorder called arginase 1 deficiency.
Health care can be one of the biggest expenses a person faces in retirement. A 65-year-old couple who retired in 2021 can expect to spend $300,000 on health care and medical expenses throughout retirement, according to the annual Fidelity Investments Retiree Health Care Cost Estimate. Despite saving and preparing their entire working lives, many people aren't mentally or financially prepared for the high cost of medical expenses in retirement.
Viagra may be able to protect people from developing Alzheimer’s disease, a new study has suggested.
Aging, the saying goes, is not for wimps. But it also doesn't have to be more difficult than necessary. Too many of us make it so, by engaging in everyday habits that can accelerate aging or significantly increase the risk of chronic disease. These are five health patterns you should never fall into after 60, according to experts. Read on to find out more—and to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID. 1 Don't Be Sedentary Many of us beco
Merck (NYSE: MRK), known as MSD outside Canada and the United States, announced today it has entered into an agreement with Thermo Fisher Scientific to manufacture molnupiravir, Merck's investigational oral antiviral medicine for the treatment of COVID-19. This agreement is part of Merck's commitment to make this investigational medicine widely available globally, if approved for use by regulatory agencies. Molnupiravir is being developed by Merck in collaboration with Ridgeback Biotherapeutics.
An American biotechnology company located in Miami of all places has convinced more than a few investors that its cellular therapy candidate can reverse common effects of aging. This November, shares of Longeveron (NASDAQ: LGVN) shot up more than 10-fold. Investors who missed the boat the first time around are wondering if Longeveron the recent slide is an opportunity to buy a potential long-term winner at a relative discount.
Feeling dehydrated after rolling up your sleeve for a vaccine? Here's what's going on.
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced JUBLIA® (efinaconazole) Topical Solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, has received the American Podiatric Medical Association (APMA) Seal of Approval. The APMA Seal of Approval is granted to products that promote good foot health and are of significant value
Stroke is a leading cause of death and disability around the globe, with approximately 800,000 people suffering a stroke each year in the U.S. alone, according to the Centers for Disease Control and Prevention (CDC). And while you may believe yourself to be at low risk for the condition, experts say that there's one type of stroke that can affect a surprising demographic: younger individuals who are in otherwise good health. That's why medical professionals are sounding the alarm about one parti
A rare heart-related health condition induced by the Covid-19 vaccine is mild and resolves quickly, according to scientists.